drugset / Trial / NCT03763370
Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
Summary
Compassionate use access to belantamab mafodotin (GSK2857916) (in combination with bortezomib/dexamethasone or pomalidomide/dexamethasone) for eligible participants with multiple myeloma previously treated with at least 1 prior line of therapy.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | 1.9 mg/kg | Intravenous |
| Subject | Belantamab mafodotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Pomalidomide | Other / unclassified | — | — |
| Background | Dexamethasone | Small molecule | — | — |